Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Elektrofi Secures $112.25M to Scale Biopharma Delivery Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Elektrofi Secures $112.25M to Scale Biopharma Delivery Technology

The funding will be used to establish Phase 3 and commercial-scale Good Manufacturing Practice (GMP) manufacturing lines.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Elektrofi Inc., a biopharmaceutical delivery technology company, has closed an upsized $112.25 million Series C financing. The round was co-led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from Eli Lilly and Company and other prominent life science investors.
 
The fresh capital will be used to establish Phase 3 and commercial-scale Good Manufacturing Practice (GMP) manufacturing lines. This expansion, coupled with the company’s first GMP line slated for early 2025, aims to accelerate the development and launch of its pipeline.
 
Elektrofi’s technology platform, Hypercon, is designed to concentrate and stabilize biopharmaceuticals, enabling self-administration and potentially expanding patient access to life-saving treatments.
 
“At Elektrofi, we envision a world in which patients have the independence they need – around how and where they take their medications – to live life on their terms,” said Chase Coffman, CEO. “The industry is on the cusp of a drug delivery revolution, and Elektrofi is proud to be leading it with Hypercon, a broadly applicable platform for the hyper concentration and stabilization of biopharmaceuticals. With our team of industry experts, distinguished Board Directors, world-class investors, and pharma partners, we look forward to scaling our proprietary technology in the interest of bringing life-changing medicines to patients across the globe as quickly as possible.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics